NDC 63323-288-01 - Naropin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-288
- Requested NDC
- 63323-288-01
- Package NDCs from labels
- 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-288-23, 63323-288-29, 63323-288-25, 63323-288-27
- Manufacturer
- Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS
- Effective date
- 2024-08-06
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | 2024-08-06 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-07-10 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | HP Halden Pharma AS | Fresenius Kabi USA, LLC | HP Halden Pharma AS | 2024-05-22 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | 2011-09-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-288-01 | Naropin | 10 mL in 1 AMPULE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-288-03 | Naropin | 10 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-288-06 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-288-07 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-288-10 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-288-11 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-288-20 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-288-21 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-288-23 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 8 | |
| 63323-288-29 | Naropin | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 8 | |
| 63323-288-25 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 5 | |
| 63323-288-27 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 27 | Current NDC, Legacy NDC, 8 package rows | 20240814_23d2d448-a744-4877-9f2d-7e57c198da89.zip |
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 8 | Current NDC, Legacy NDC, 2 package rows | 20240817_c6613708-c1f7-4f5c-91a3-ebbc1d7905c6.zip |
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC] | 5 | Current NDC, Legacy NDC, 2 package rows | 20240524_56dfabf7-f7a8-4601-b17a-cb16fb995b0f.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-288-01 | ML - Milliliter | 63323-288 | 99d30a29-0827-4f56-871e-74fff2b21d2a | 1 | 2025-09-12 |
| 63323-288-06 | ML - Milliliter | 63323-288 | 0b27ce34-0c40-470b-baa5-cd6d736138a9 | 1 | 2021-06-02 |
| 63323-288-07 | ML - Milliliter | 63323-288 | e450eecd-0e8b-4c29-8b4e-70132736db56 | 1 | 2024-08-12 |
| 63323-288-10 | ML - Milliliter | 63323-288 | 3332880c-79cc-46fc-b3fe-0d5e98caedb9 | 1 | 2012-07-24 |
| 63323-288-11 | ML - Milliliter | 63323-288 | cfbf6146-ab02-4290-b393-9e6cf57f0bdb | 1 | 2013-02-13 |
| 63323-288-20 | ML - Milliliter | 63323-288 | d1bf23e5-a796-4fd1-be7d-d04e794afc02 | 1 | 2012-07-24 |
| 63323-288-21 | ML - Milliliter | 63323-288 | 28b72b1c-78b4-463a-baf5-f1249b7071d8 | 1 | 2013-02-13 |
| 63323-288-23 | ML - Milliliter | 63323-288 | 57c7d0ae-4b9d-4fa9-a9b4-015794be2d20 | 1 | 2024-07-12 |
| 63323-288-27 | ML - Milliliter | 63323-288 | 67d56f56-df1f-4127-896a-1e29cb3fd63f | 1 | 2014-04-03 |
| 63323-288-29 | ML - Milliliter | 63323-288 | f2b1e7d0-d777-41f2-a2a2-b4a33d62a096 | 1 | 2014-04-03 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Viril | BENZOICUM ACIDUM, CALADIUM SEGUINUM, CHIMAPHILA UMBELLATA, CLEMATIS ERECTA, RHODODENDRON, SABAL SERRULATA, NATRUM MURIATICUM, CORTISONE ACETICUM, HYPOTHALAMUS SUIS, PROSTATE (SUIS), TESTOSTERONE, AGNUS CASTUS, AURUM METALLICUM, BRYONIA (ALBA), CONIUM MACULATUM, LYCOPODIUM CLAVATUM, SELENIUM METALLICUM, SEPIA, THUJA OCCIDENTALIS, KALI ARSENICOSUM, BUFO RANA | Deseret Biologicals, Inc. | 3701cc0d-91ed-45fd-98b8-9d8cfba9c787 | 2026-05-06 | Warnings | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | Sportpharm LLC | a2c111f6-74d5-4a5d-82ac-d0f237488cb8 | 2026-04-24 | Warnings, Adverse reactions | 451W47IQ8X |
| Ropivacaine Hydrochloride | ROPIVACAINE HYDROCHLORIDE | Sportpharm LLC | 56b664ad-03e0-4bf3-8efa-40ce3e8d3498 | 2026-04-24 | Warnings, Adverse reactions | 1734475 V910P86109 |
| Ropivacaine Hydrochloride | ROPIVACAINE HYDROCHLORIDE | Sportpharm LLC | 7327766c-19f0-4d83-89c6-eb685e0d286c | 2026-04-24 | Warnings, Adverse reactions | 1734475 V910P86109 |
| Sodium Chloride | SODIUM CHLORIDE | Method Pharmaceuticals, LLC | 4b08859e-65bd-8255-e063-6394a90af614 | 2026-04-23 | Warnings | 451W47IQ8X |
| Ropivacaine Hydrochloride | ROPIVACAINE HYDROCHLORIDE | Eugia US LLC | 3763b7b6-da49-4658-b93d-28f5da24d09e | 2026-04-21 | Warnings, Adverse reactions | 1734090 1734483 1734207 1734475 1734084 1734347 905189 V910P86109 |
| Ringers | SODIUM CHLORIDE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE | ICU Medical, Inc. | a926f913-18fa-4a3e-bfd6-210e1e427960 | 2026-04-20 | Warnings, Adverse reactions | 451W47IQ8X |
| Cardioforce II | ABROTANUM, BOLDO, CIMICIFUGA RACEMOSA, KALI PHOSPHORICUM, TARAXACUM OFFICINALE, CONVALLARIA MAJALIS, MAGNESIA SULPHURICA, OLEANDER, NATRUM MURIATICUM, BELLIS PERENNIS | BioActive Nutritional, Inc. | 733bbb26-7698-4a1b-9dc8-7e3490ffc92b | 2026-04-17 | Warnings | 451W47IQ8X |
| Thyroid HP | BARYTA CARBONICA, CALCAREA CARBONICA, FUCUS VESICULOSUS, IODIUM, NATRUM MURIATICUM, PULSATILLA, SPONGIA TOSTA, THYROIDINUM (SUIS) | BioActive Nutritional, Inc. | 3795820a-cf2a-4094-9a02-70e3757b7510 | 2026-04-17 | Warnings | 451W47IQ8X |
| DIANEAL Low Calcium with Dextrose | SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE | Vantive US Healthcare LLC | aa268d3f-7389-4f25-801f-5d4825495f08 | 2026-04-16 | Warnings, Adverse reactions | 451W47IQ8X |
| PEG 3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | b251752d-7750-482a-9364-0acf4ad47cc8 | 2026-04-16 | Warnings, Adverse reactions | 451W47IQ8X |
| Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE | Fresenius Kabi USA, LLC | 99c6a1a9-cadf-435b-a332-ccc189afdfa9 | 2026-04-16 | Warnings, Adverse reactions | 451W47IQ8X |
| GoLYTELY | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Azurity Pharmaceuticals, Inc. | 7609ecf7-0ce0-4fbb-9c27-30987f689575 | 2026-04-15 | Warnings, Adverse reactions | 451W47IQ8X |
| TRILYTE | POLYETHYLENE GLYOCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE AND POTASSIUM CHLORIDE | Aurobindo Pharma Limited | 79f5e596-8d51-4227-afcc-f5e341150957 | 2026-04-15 | Warnings, Adverse reactions | 451W47IQ8X |
| Anxiety Relief | ACONITUM NAPELLUS, ARGENTUM NITRICUM, ARSENICUM ALBUM, AURUM METALLICUM, GELSEMIUM SEMPERVIRENS, HYOSCYAMUS NIGER, IGNATIA AMARA, KALI CARBONICUM, MOSCHUS, NATRUM MURIATICUM, PIPER METHYSTICUM | NaturalCare | 9f982e89-655c-49be-85d8-4099a02ed021 | 2026-04-15 | Warnings | 451W47IQ8X |
| PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride | POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | 4e442a72-b13b-4869-8a1d-59356095b091 | 2026-04-14 | Warnings, Adverse reactions | 451W47IQ8X |
| SODIUM CHLORIDE 1 GRAM | SODIUM CHLORIDE | Gendose Pharmaceuticals, LLC | ce988ae5-61c6-4324-90e1-a94c8a54d0d0 | 2026-04-13 | Warnings | 451W47IQ8X |
| Quantum Resonance | ALCOHOLUS, ALUMINA SILICATA, ANACARDIUM ORIENTALE, AQUA MARINA, BAPTISIA TINCTORIA, CANDIDA ALBICANS, COLLAGEN, DNA, LAVANDULA OFFICINALIS, MEDULLA OSSIS SUIS, NATRUM MURIATICUM, NATRUM PHOSPHORICUM, NUX MOSCHATA, PHOSPHORUS, QUARTZ, SILICEA, TELA ARANEA, VALERIANA OFFICINALIS, VISCUM ALBUM | Deseret Biologicals, Inc. | f94a10bd-1c40-42c7-b458-b58070614549 | 2026-04-10 | Warnings | 451W47IQ8X |
| Quantum Resonance | ALCOHOLUS, ALUMINA SILICATA, ANACARDIUM ORIENTALE, AQUA MARINA, BAPTISIA TINCTORIA, CANDIDA ALBICANS, COLLAGEN, DNA, LAVANDULA OFFICINALIS, MEDULLA OSSIS SUIS, NATRUM MURIATICUM, NATRUM PHOSPHORICUM, NUX MOSCHATA, PHOSPHORUS, QUARTZ, SILICEA, TELA ARANEA, VALERIANA OFFICINALIS, VISCUM ALBUM | Deseret Biologicals, Inc. | 1467111a-bef6-473d-b7f2-3309a9bb72ce | 2026-04-10 | Warnings | 451W47IQ8X |
| H-Focus Formula | AGNUS CASTUS, AVENA SATIVA, BARYTA CARBONICA, IGNATIA AMARA, LYCOPODIUM CLAVATUM, NATRUM CARBONICUM, NATRUM MURIATICUM, PHOSPHORICUM ACIDUM, SILICEA, ZINCUM METALLICUM | Healing Natural Oils LLC | 4ee42911-3064-7f55-e063-6294a90abcc7 | 2026-04-07 | Warnings | 451W47IQ8X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.